Sunday, August 31, 2025 8/31/2025

Elucidating the mechanism of erythropoietin (EPO) in mitigating Dry-AMD pathophysiology

Award Number: R01EY033415
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Elucidating the mechanism of erythropoietin (EPO) in mitigating Dry-AMD pathophysiology - PROJECT SUMMARY Age-related macular degeneration (AMD) is one of the leading causes of irreversible visual dysfunction in older individuals in developed countries, resulting in loss of productivity, independence, and quality of life, as well as tremendous healthcare and economic burden. Visual dysfunction in AMD patients could be in the form of ‘‘dry’’ AMD or ‘‘wet’’ AMD or both. While some treatments are available for wet-AMD, but there is no effective treatment for geographic atrophy (GA), the advanced form of dry-AMD. Oxidative stress-induced cellular changes play a significant role in the loss of macular RPE and photoreceptors in dry-AMD. Treatments involving local and sustained delivery of molecules or genes to counteract oxidative stress-induced cellular changes could prevent RPE atrophy. Systemic or retinal delivery EPO-R76E, a modified form of EPO (with reduced erythropoietic activity) improved the function of ganglion cells and photoreceptors cells in the retina. Because of its effect in preventing cell death due to induction oxidative stress, we are especially interested in investigating the precise mechanism(s) of how RPE specific EPO-R76E interacts with other retinal cells and influences aberrant molecular pathways in controlling dry-AMD phenotype. We will interrogate the impact of EPO-R76E using two different animal models showing AMD pathology; one is associated with induction of RPE oxidative stress, and the other due to complement dysregulation. We will use recombinant adeno-associated virus (AAV) with serotype 1 to achieve sustained expression of EPO-R76E and deliver to mice eye via subretinal injection. Our first aim will test molecular mechanisms of the retinal protection by EPO-R76E using proteomics analyses of pathways and cell- specific transcriptional approaches in a mouse model of dry-AMD. Our second aim will test whether sustained expression of EPO-R76E ameliorates dry AMD phenotypes in animal models and interrogate how late in the course of retinal degeneration EPO-R76E will be effective in preventing disease symptoms. Our research will elucidate the role of EPO signaling in RPE function, retinal health, and the approach for preventive or therapeutic intervention of dry-AMD. These studies will identify novel molecular pathways for manipulating the retina and provide a new direction for managing dry-AMD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $412,853 )
2025	2025	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Vision Research	000	4	8/4/2025	NON-COMPETING CONTINUATION	$412,853
														Subtotal = $412,853

Issue Date FY: 2024 ( Subtotal = $412,853 )
2024	2024	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Vision Research	000	3	7/24/2024	NON-COMPETING CONTINUATION	$412,853
														Subtotal = $412,853

Issue Date FY: 2023 ( Subtotal = $412,738 )
2023	2023	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Vision Research	000	2	5/30/2023	NON-COMPETING CONTINUATION	$412,738
														Subtotal = $412,738

Issue Date FY: 2022 ( Subtotal = $411,476 )
2022	2022	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Vision Research	000	1	8/31/2022	NEW	$411,476
														Subtotal = $411,476

Grand Total All Awards = $1,649,920

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Elucidating the mechanism of erythropoietin (EPO) in mitigating Dry-AMD pathophysiology

Award Number: R01EY033415

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer